And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
After a hiatus Nkarta comes back with a new lymphodepletion regimen to boost its lead Car-NK therapy.
But it still has a long way to go with its islet cell therapies.
The private group celebrates a double first for its mRNA-generated Car-T therapy in myasthenia gravis.
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.
Astrazeneca’s $85m Quell collaboration comes after Regeneron’s tie-up with Sonoma and Lilly’s deal with Trex.
Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.
T-cell exhaustion, a frequently cited reason for Car-T relapse, might be reversed by PD-(L)1 blockade; but is exhaustion really the problem?